GI Oncology Now

📺 In another discussion with Shubham Pant of MD Anderson Cancer Center from the American Society of Clinical Oncology (ASCO)'s #GI25 symposium, he reviews new updates on a phase 1b dose escalation trial of #gemcitabine and nab-paclitaxel in combination with #lixumistat in patients with advanced #pancreatic cancer: https://buff.ly/3WRqGX6

📺 In part two of our interview with Marwan Fakih of City of Hope, he discusses the objective response rate of #botensilimab with #balstilimab for metastatic colorectal cancer, and how the treatment can potentially redefine treatment paradigms in the future: https://buff.ly/4jRERoM

📺 At the American Society of Clinical Oncology (ASCO)'s #GU25 symposium, Tsuyoshi Shirakawa, MD, PhD, of the Oncology Treatment Study Group, highlighted the results of the NAPOLEON-2 trial, including how the real-world data from the study compares to clinical trial findings in terms of the frequency and severity of neutropenia observed with nanoliposomal #irinotecan and #fluorouracil with folinic acid: https://buff.ly/4gursQF

📺 Dr. Thierry André, head of the Medical Oncology Department at Hôpital Saint-Antoine, discusses the CheckMate 8HW study presented at @ASCO #GI25 on #nivolumab plus #ipilimumab versus nivolumab monotherapy in MSI-H/dMMR metastatic colorectal cancer in a new interview:

🥄 At the American Society of Clinical Oncology (ASCO)'s #GI25 symposium, Boris Pasche of Karmanos Cancer Institute gave an overview of the TheraBionic P1 device and how it works as a systemic targeted therapy for advanced hepatocellular carcinoma. 📺 Learn more about how the device works: https://buff.ly/3Q9SQc2

📺 In a recent interview, Dr. Marwan Fakih of City of Hope discusses the phase 2 study of #botensilimab + #balstilimab for the treatment of refractory microsatellite stable metastatic #colorectal cancer with no liver metastases that was presented at ASCO #GI25: https://lnkd.in/eYKvzUxE

⭐ Our new roundtable moderated by Dr. Yelena Janjigian of Memorial Sloan Kettering Cancer Center featured Drs. Mohamad Bassam Sonbol of Mayo Clinic, Sakti Chakrabarti of University Hospitals, Samuel Cytryn of Memorial Sloan Kettering Cancer Center, and Mariela Blum Murphy of MD Anderson Cancer Center in a discussion on the upper GI treatment landscape. 📺 In the first segment of their conversation, the panelists discuss cutting-edge advancements in biomarker-driven strategies for treating #gastric and #esophageal adenocarcinomas: https://buff.ly/4jEDN7T

📰 As the survival benefits of neoadjuvant #chemotherapy are inconsistent for patients with locally advanced #gastric cancer, a recent study sought to determine how different tumor regression grades impact the survival gains linked to treatment with NAC:

📺 Check out our interview with Scott Kopetz of MD Anderson Cancer Center on the phase 3 BREAKWATER study. 👉 The study analyzed 1L #encorafenib and #cetuximab with FOLFOX against standard-of-care chemotherapy alone for BRAF V600E-mutant metastatic #colorectal cancer: https://buff.ly/4gwwgVA

📺 We spoke with Dr. Shubham Pant of MD Anderson Cancer Center at the American Society of Clinical Oncology (ASCO)'s #GI25 symposium on the latest update from the HERIZON-BTC-01 trial, which highlighted the efficacy of #zanidatamab over standard-of-care therapies in HER2-positive biliary tract cancer: https://buff.ly/3EsADE8